LB Pharmaceuticals’ Loss Reaches $59.1 Million As LB-102 Trial Costs Climb
The drug developer expects its $403.8 million in cash and investments to support operations beyond the second quarter of 2029.
LB Pharmaceuticals, which develops medicines for neuropsychiatric disorders, reported a third-quarter net loss of $59.1 million Thursday, compared with $3.6 million a year earlier, in results accompanying an SEC filing. Spending on trials of its experimental drug LB-102 drove the increase in research costs, while management expects its cash and investments to cover planned operations beyond the second quarter of 2029.
LB-102 Drives Research Spending
Research expenses reached $51.5 million in the third quarter, compared with $2.4 million a year earlier. The company attributed the increase primarily to its late-stage schizophrenia trial and mid-stage bipolar depression trial.
Administrative expenses were $11.0 million, versus $2.8 million a year earlier. A larger workforce brought higher cash and non-cash pay costs, alongside increased consulting spending and the expense of operating as a public company.
The first nine months show the same spending pattern: research expenses totaled $110.3 million, against $8.3 million a year earlier, and administrative expenses reached $28.2 million, also against $8.3 million. The nine-month net loss was $129.7 million, compared with $13.7 million.
Funding A Broader Drug Program
Cash, cash equivalents and short-term investments stood at $403.8 million on September 30. The company’s forecast that this money will support operations beyond the second quarter of 2029 depends on its current operating assumptions.
A July 2026 private placement brought in $150.0 million from new and existing institutional investors, with approximately $140.9 million remaining after financing expenses. Those proceeds are intended for general corporate purposes and expansion into additional uses, potentially including schizophrenia’s negative symptoms and Alzheimer’s disease psychosis and agitation.
LB-102 is an experimental oral antipsychotic taken once daily. LB Pharmaceuticals owns global rights to the drug and is also developing a long-acting injectable version. Its program targets psychiatric symptoms affecting thinking, motivation and mood.
The company announced Susan G. Kozauer as chief medical officer and Joseph Miller as chief financial officer in September 2026. In October 2026, management held a research-and-development event featuring Roger McIntyre and presented four posters at the 39th European College of Neuropsychopharmacology Congress covering preclinical findings and the schizophrenia program.
Schizophrenia Results Lead The Calendar
“We remain on track to report topline results from our Phase 3 NOVA-2 trial of LB-102 in schizophrenia in the first half of 2027,” said Heather Turner, chief executive officer of LB Pharmaceuticals.
The company expects to schedule a meeting with the FDA about a potential approval application in the second half of 2027. A separate 52-week study of long-term safety and tolerability continues to enroll patients with stable schizophrenia, including participants who completed the late-stage trial.
Following discussions with the FDA, management expects to update investors on a possible trial design for predominantly negative symptoms of schizophrenia in the first quarter of 2027. Its ongoing mid-stage bipolar 1 depression trial is expected to produce results in the first quarter of 2028.
A mid-stage trial testing LB-102 as an additional treatment for major depressive disorder is expected to begin in early 2027, with results expected in the first half of 2029.
Sources
- 8-K Filing — LB PHARMACEUTICALS INC (LBRX) — SEC EDGAR
- Exhibit d167920dex991.htm — LB PHARMACEUTICALS INC 8-K exhibit — SEC EDGAR
- LB Pharmaceuticals GAAP EPS of -$1.79 | Seeking Alpha — seekingalpha.com